CCM
PBYI icon

Causeway Capital Management’s Puma Biotechnology PBYI Stock Holding History

Causeway Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,310
Closed -$79.2K – 117
2025
Q4 		$79.2K Sell
13,310
-785
-6% -$4.17K ﹤0.01% 107
2025
Q3 		$74.8K Hold
14,095
– – ﹤0.01% 105
2025
Q2 		$48.3K Hold
14,095
– – ﹤0.01% 99
2025
Q1 		$41.7K Buy
+14,095
New +$44.1K ﹤0.01% 90

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Causeway Capital Management's PBYI Position: Q1 2026 in Review

Causeway Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 13,310 shares — an estimated $79.2K sold.

Causeway Capital Management first reported a position in PBYI in Q1 2025 and held it in 4 quarters. The position peaked at $79.2K in Q4 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Causeway Capital Management reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Causeway Capital Management sold 13,310 Puma Biotechnology shares in Q1 2026, an estimated $79.2K.
  • Causeway Capital Management first reported a position in Puma Biotechnology in Q1 2025 and held it in 4 quarters.
  • Causeway Capital Management's Puma Biotechnology position peaked at $79.2K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Causeway Capital Management's 13F filing for Q1 2026, filed 14 May 2026.